A study to evaluate the safety and efficacy of Pola in combination with R-GemOx (rituximab, gemcitabine, and oxaliplatin) compared to R-GemOx alone in R/R DLBCL patients (POLARGO, NCT04182204) is ongoing. The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.